Mortality data for scleroderma derived from death certificates from England and Wales for the years 1968-1985 were analysed. The overail crude mortalities were 0-9 and 3-8 per million per year in men and women respectively, which are similar to comparable data from the United States. There has been a small but statistically significant increase in mortality of 3% a year over this period, possibly reflecting an underlying increasing trend in incidence. Such crude and the age and sex specific annual mortalities were calculated as the average annual mortality over the 12 year period [1974][1975][1976][1977][1978][1979][1980][1981][1982][1983][1984][1985] using million person years at risk in each age sex group over this period as the denominator. Trends during the period of observation were compared by examining three year moving averages-that is, the mean annual mortality during 1968-1970, 1969-1971, etc-to reduce the effect of random variation from a single year's data. These average annual rates were adjusted for age and sex using indirect standardisation taking the 12 year age and sex specific rates calculated above as those of the standard population. Linear regression was used to assess the magnitude and significance of any underlying trend. There were virtually no deaths from scleroderma in children during this period, and thus all rates are based on the adult (aged 15+) population.
Population mortalities for diseases such as scleroderma, which are both rare and have a relatively high fatality rate, can provide an alternative to the more costly and time consuming multicentre surveys in yielding estimates of incidence. Additionally, if the natural history and response to treatment are relatively constant, both over time and between different populations, then a comparison of mortalities can provide a guide to both time and geographical trends in incidence. Furthermore, knowledge of both the incidence and mortality for scleroderma within the same population can be used to crude and the age and sex specific annual mortalities were calculated as the average annual mortality over the 12 year period [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] using million person years at risk in each age sex group over this period as the denominator. Trends during the period of observation were compared by examining three year moving averages-that is, the mean annual mortality during [1968] [1969] [1970] [1969] [1970] [1971] , etc-to reduce the effect of random variation from a single year's data. These average annual rates were adjusted for age and sex using indirect standardisation taking the 12 year age and sex specific rates calculated above as those of the standard population. Linear regression was used to assess the magnitude and significance of any underlying trend. There were virtually no deaths from scleroderma in children during this period, and thus all rates are based on the adult (aged 15+) population.
Results
The results show overall mortalities of 0 9 and 3-8 per million per year in men and women respectively. Figure 1 The average increase in annual mortality of 3% approximates to a total increase of around 50% during the entire period. It seems unlikely that patient survival has deteriorated; if anything the use of agents such as captopril has improved the outlook in severe renal diseases. 8 The possibility that the increase in mortality reflects differences in death certificate coding or completion remains unanswered. There is no a priori reason, however, to suspect that this occurred in either direction or specifically towards an increased mention of scleroderma. More probably, perhaps, scleroderma is increasing in incidence in England and Wales, reflecting a similar increase, based on clinically ascertained cases, in the United States. 9 It is perhaps reassuring that the rates obtained in this study are close to those found by a similarly conducted analysis in the United States.2 The total population mortalities in that population were 1 5 and 3 -5 per million per year in men and women respectively, figures which were also similar to data gathered some 10-15 years earlier in the United States.'
There are few data on the incidence of scleroderma in the United Kingdom. Such data that are available suggest a minimum incidence, based on diagnosed patients attending hospital, of 1 1 and 6 per million per year in men and women respectively.'0 These estimates would suggest therefore that about 60% of women and an even higher proportion of men with scleroderma ultimately die from their disease. These figures seem very high, though they are comparable with survival data from the largest series of 309 patients in the United States, which suggested a nine year corrected mortality of about 62%."1 Many cases of scleroderma are probably undiagnosed in the community'2 and thus would not appear in either incidence or survival data generated from hospital attenders. The 'hospital' incidence of scleroderma, as stated, is apparently increasing,9 though this in part might be due to greater ascertainment of less severe cases, and thus future studies of outcome might show a more favourable prognosis.
In conclusion, mortality from scleroderma in England and Wales is broadly similar to that in the United States, and the underlying incidence and increasing trend of the disease in the two countries is probably the same. Further, these mortality data, albeit with their imperfections, reinforce the results from hospital series of a high ultimate fatality from this disease in patients diagnosed in hospital.
